✦ LIBER ✦

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: An Illinois cancer center study

✍ Scribed by Jacob Lokich; Timothy M. Kuzel; Martin S. Tallman

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 192 KB
Volume: 73
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940301)73:5<1536::aid-cncr2820730538>3.0.co;2-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of continuous infusion

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

✍ Timothy M. Kuzel; Martin S. Tallman; Daniel Shevrin; Edward Braud; Lary Kilton; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB 👁 2 views

A phase II study of recombinant human al

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer

✍ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas

A phase II study of combined 5-fluoroura

A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer

✍ Willy Mattsson; Finn Von Eyben; Lennart Hallsten; Göran Bjelkengren 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views

In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Continuous infusion of high-dose 5-fluor

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

✍ Cornelis J. A. Punt; Jos Th. M. Burghouts; Jelle J. Croles; Peter A. van Liessum 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

Phase II study of 5-fluorouracil and fol

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study

✍ Giuseppe Colucci 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our